This database contains 59 studies, archived under the term: "efficacy"
Click here to filter this large number of results.
Two galantamine titration regimens in patients switched from donepezil
Engedal, K.,
Davis, B.,
Richarz, U.,
Han, J.,
Schäuble, B.,
Andreasen, N.
Objectives: In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease (AD), but also for those who have not benefited from their current therapy. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability […]
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease
Salloway, Stephen,
Mintzer, Jacobo,
Cummings, Jeffrey L.,
Geldmacher, David,
Sun, Yijun,
Yardley, Jane,
Mackell, Joan
To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil […]
Psychosocial group intervention to enhance self-management skills of people with dementia and their caregivers: study protocol for a randomized controlled trial
Laakkonen, Marja-Liisa,
Hölttä, Eeva H.,
Savikko, Niina,
Strandberg, Timo E.,
Suominen, Merja,
Pitkälä, Kaisu H.
Background: After diagnosis of a dementing illness, patients and their spouses have many concerns related to the disease and their future. This often leads to poor psychological well-being and reduced health-related quality of life (HRQoL) of the family. Support for self-management skills has been proven to be an effective method to improve prognosis of asthma, […]
CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial
Kurz, Alexander,
Thöne-Otto, Angelika,
Cramer, Barbara,
Egert, Silvia,
Frölich, Lutz,
Gertz, Hermann-Josef,
Kehl, Victoria,
Wagenpfeil, Stefan,
Werheid, Katja
Cognitive rehabilitation (CR) is a promising treatment approach for older adults with dementia because it aims at supporting the management of day-to-day problems. There is insufficient evidence regarding whether CR provides clinically meaningful benefits. In this study, we evaluated the feasibility, acceptance, efficacy, and usefulness of a CR intervention in a multicenter, randomized, controlled trial […]
Passive movement therapy in severe paratonia: a multicenter randomized clinical trial
Background: Paratonia causes severe movement dysfunction in late stage dementia. Passive Movement Therapy (PMT) is often used to decrease high muscle tone, but the efficacy has never been shown. The objective of this study is to investigate the effect of PMT on muscle tone after two and four weeks of treatment.; Methods: This study comprised […]
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
Howard, Robert,
McShane, Rupert,
Lindesay, James,
Ritchie, Craig,
Baldwin, Ashley,
Barber, Robert,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Jones, Rob,
Jones, Roy,
McKeith, Ian,
Macharouthu, Ajay,
O'Brien, John,
Passmore, Peter,
Sheehan, Bart,
Juszczak, Edmund,
Katona, Cornelius,
Hills, Robert,
Knapp, Martin,
Ballard, Clive,
Brown, Richard,
Banerjee, Sube,
Onions, Caroline,
Griffin, Mary,
Adams, Jessica,
Gray, Richard,
Johnson, Tony,
Bentham, Peter,
Phillips, Patrick
Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Cognitive stimulation therapy (CST) for people with dementia–who benefits most?
Aguirre, E.,
Hoare, Z.,
Streater, A.,
Spector, A.,
Woods, B.,
Hoe, J.,
Orrell, M.
Background: The efficacy of cognitive stimulation therapy (CST) has been demonstrated, but little is known about the characteristics of people with dementia, which may predict a more positive response to CST. This study sought to investigate which factors may predict response to CST.; Methods: Two hundred and seventy-two participants with dementia took part in a […]
Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study
Dubois, Bruno,
Tolosa, Eduardo,
Katzenschlager, Regina,
Emre, Murat,
Lees, Andrew J.,
Schumann, Günther,
Pourcher, Emmanuelle,
Gray, Julian,
Thomas, Gail,
Swartz, Jina,
Hsu, Timothy,
Moline, Margaret L.
Parkinson’s disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and […]